Abstract
The metallocene dihalides are a relatively new class of small, hydrophobic organometallic anticancer agents that exhibit antitumour properties against numerous cell lines including leukemias P388 and L1210, colon 38 and Lewis lung carcinomas, B16 melanoma, solid and fluid Ehrlich ascites tumours and several human colon and lung carcinomas transplanted into athymic mice. Titanocene dichloride 1 has been the most widely studied metallocene and the drug is currently in phase II clinical trials. Formation of metallocene-DNA complexes has been implicated in the mechanism of antitumour properties of the metallocenes, as both titanocene dichloride 1 and vanadocene dichloride 2 inhibit DNA and RNA synthesis, and titanium and vanadium accumulate in nucleic acid-rich regions of tumour cells. However, in contrast to the well characterized platinum-based anticancer drugs, the active species responsible for antitumour activity in vivo has not been identified and the mechanism whereby irreparable DNA damage and/or structural modification of DNA or other cellular targets occurs is poorly understood. This review will focus on recent studies that have been carried out in order to identify the biologically active species and more fully understand the molecular level mechanism of action of the metallocene dihalides. Studies with nucleotides, oligonucleotides, DNA and proteins including topoisomerases, protein kinase C and transferrin have provided important insight into potential cellular transport mechanisms and the interaction of metallocenes with biomolecular targets. New structure activity studies including the design of hydrolytically stable metallocenes and the preparation of highly water soluble amino acid analogues have not led to improved anticancer activity of titanocene dichloride 1. The vastly different chemical and hydrolytic stability of each of the metallocenes points to a unique mechanism of action of each metallocene in vivo.
Current Medicinal Chemistry
Title: Antitumour Metallocenes: Structure-Activity Studies and Interactions with Biomolecules.
Volume: 7 Issue: 12
Author(s): Margaret M. Harding and George Mokdsi
Affiliation:
Abstract: The metallocene dihalides are a relatively new class of small, hydrophobic organometallic anticancer agents that exhibit antitumour properties against numerous cell lines including leukemias P388 and L1210, colon 38 and Lewis lung carcinomas, B16 melanoma, solid and fluid Ehrlich ascites tumours and several human colon and lung carcinomas transplanted into athymic mice. Titanocene dichloride 1 has been the most widely studied metallocene and the drug is currently in phase II clinical trials. Formation of metallocene-DNA complexes has been implicated in the mechanism of antitumour properties of the metallocenes, as both titanocene dichloride 1 and vanadocene dichloride 2 inhibit DNA and RNA synthesis, and titanium and vanadium accumulate in nucleic acid-rich regions of tumour cells. However, in contrast to the well characterized platinum-based anticancer drugs, the active species responsible for antitumour activity in vivo has not been identified and the mechanism whereby irreparable DNA damage and/or structural modification of DNA or other cellular targets occurs is poorly understood. This review will focus on recent studies that have been carried out in order to identify the biologically active species and more fully understand the molecular level mechanism of action of the metallocene dihalides. Studies with nucleotides, oligonucleotides, DNA and proteins including topoisomerases, protein kinase C and transferrin have provided important insight into potential cellular transport mechanisms and the interaction of metallocenes with biomolecular targets. New structure activity studies including the design of hydrolytically stable metallocenes and the preparation of highly water soluble amino acid analogues have not led to improved anticancer activity of titanocene dichloride 1. The vastly different chemical and hydrolytic stability of each of the metallocenes points to a unique mechanism of action of each metallocene in vivo.
Export Options
About this article
Cite this article as:
Harding M. Margaret and Mokdsi George, Antitumour Metallocenes: Structure-Activity Studies and Interactions with Biomolecules., Current Medicinal Chemistry 2000; 7 (12) . https://dx.doi.org/10.2174/0929867003374066
DOI https://dx.doi.org/10.2174/0929867003374066 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments of Rebeccamycin Analogues as Topoisomerase I Inhibitors and Antitumor Agents.
Current Medicinal Chemistry A Role of DEAD-Box RNA Helicase rck/p54 in Cancer Cells
Current Drug Therapy Novel Dual Inhibitors of Nuclear Factor-Kappa B (NF-κ B) and Cyclooxygenase- 2 (COX-2): Synthesis, In Vitro Anticancer Activity and Stability Studies of Lantadene–Non Steroidal Anti-inflammatory Drug (NSAID) Conjugates
Current Topics in Medicinal Chemistry Repurposing Drugs for Cancer Prevention
Current Topics in Medicinal Chemistry Targeting Apoptosis Pathway with Natural Terpenoids: Implications for Treatment of Breast and Prostate Cancer
Current Drug Targets Encapsulation of Imatinib in Targeted KIT-5 Nanoparticles for Reducing its Cardiotoxicity and Hepatotoxicity
Anti-Cancer Agents in Medicinal Chemistry RNAi in Clinical Studies
Current Medicinal Chemistry Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science Immunotherapy of HCC
Reviews on Recent Clinical Trials Metabolic Homeostasis and Colonic Health: the Critical Role of Short Chain Fatty Acids
Current Nutrition & Food Science TWIST1 Gene: First Insights in Felis catus
Current Genomics Effect of Some Triterpene Glycosides Applied in vitro on Chromatin State in Human Cells
Current Bioactive Compounds Nanomaterials for Deep Tumor Treatment
Mini-Reviews in Medicinal Chemistry Recent Patents in Oncolytic Virotherapy
Recent Patents on Biotechnology Recent Advances in Superparamagnetic Iron Oxide Nanoparticles for Cellular Imaging and Targeted Therapy Research
Current Pharmaceutical Design Chemotherapy for Laryngeal Cancer - An Apoptotic Approach
Current Drug Targets PI3K Inhibitors for Cancer Therapy: What has been Achieved So Far?
Current Medicinal Chemistry The Importance of Lamivudine Therapy in Liver Cirrhosis Patients Related HBV with Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy
Clinical Cancer Drugs A Novel Fusicoccin Derivative Preferentially Targets Hypoxic Tumor Cells and Inhibits Tumor Growth in Xenografts
Anti-Cancer Agents in Medicinal Chemistry New Perspectives in the Pharmacological Treatment of Non-Melanoma Skin Cancer
Current Drug Targets